These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 23141847

  • 41. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
    Moreno-Arribas J, Bertomeu-González V, Anguita-Sanchez M, Cequier Á, Muñiz J, Castillo J, Sanchis J, Roldán I, Marín F, Bertomeu-Martínez V, investigators of the FANTASIIA study.
    J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096
    [Abstract] [Full Text] [Related]

  • 42. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.
    Leey JA, McCabe S, Koch JA, Miles TP.
    Am J Geriatr Pharmacother; 2009 Aug; 7(4):197-203. PubMed ID: 19766951
    [Abstract] [Full Text] [Related]

  • 43. [Anticoagulation and atrial fibrillation].
    Simmers TA.
    Tijdschr Gerontol Geriatr; 2012 Dec; 43(6):308-12. PubMed ID: 23371873
    [Abstract] [Full Text] [Related]

  • 44. Comparison of HAS-BLED and HAS-BED Versus CHADS2 and CHA2DS2VASC Stroke and Bleeding Scores in Patients With Atrial Fibrillation.
    Poli D, Antonucci E, Pengo V, Testa S, Palareti G.
    Am J Cardiol; 2017 Apr 01; 119(7):1012-1016. PubMed ID: 28237286
    [Abstract] [Full Text] [Related]

  • 45. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.
    Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunsø J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C.
    Thromb Haemost; 2011 Oct 01; 106(4):739-49. PubMed ID: 21789337
    [Abstract] [Full Text] [Related]

  • 46. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
    ROCKET AF Study InvestigatorsDuke Clinical Research Institute, Durham, NC, USA..
    Am Heart J; 2010 Mar 01; 159(3):340-347.e1. PubMed ID: 20211293
    [Abstract] [Full Text] [Related]

  • 47. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients.
    Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, Valdés M, Vicente V, Lip GYH, Marín F.
    Thromb Haemost; 2017 Jun 27; 117(7):1448-1454. PubMed ID: 28331926
    [Abstract] [Full Text] [Related]

  • 48. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.
    Haas S, Ten Cate H, Accetta G, Angchaisuksiri P, Bassand JP, Camm AJ, Corbalan R, Darius H, Fitzmaurice DA, Goldhaber SZ, Goto S, Jacobson B, Kayani G, Mantovani LG, Misselwitz F, Pieper K, Schellong SM, Stepinska J, Turpie AG, van Eickels M, Kakkar AK, GARFIELD-AF Investigators.
    PLoS One; 2016 Jun 27; 11(10):e0164076. PubMed ID: 27792741
    [Abstract] [Full Text] [Related]

  • 49. Vitamin K antagonists in patients with nonvalvular atrial fibrillation: appropriateness and quality of treatment in an Italian cohort.
    Pereira de Sousa L, Burba I, Ruperto C, Lattuada L, Barbone F, Di Chiara A.
    J Cardiovasc Med (Hagerstown); 2013 Jul 27; 14(7):534-40. PubMed ID: 23328227
    [Abstract] [Full Text] [Related]

  • 50. Antithrombotic prophylaxis in elderly patients with atrial fibrillation.
    Hylek EM.
    Semin Thromb Hemost; 2009 Sep 27; 35(6):548-53. PubMed ID: 19787558
    [Abstract] [Full Text] [Related]

  • 51. Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls.
    Garwood CL, Corbett TL.
    Ann Pharmacother; 2008 Apr 27; 42(4):523-32. PubMed ID: 18334606
    [Abstract] [Full Text] [Related]

  • 52. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
    Agarwal S, Hachamovitch R, Menon V.
    Arch Intern Med; 2012 Apr 23; 172(8):623-31; discussion 631-3. PubMed ID: 22450212
    [Abstract] [Full Text] [Related]

  • 53. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation.
    Lip GY, Frison L, Grind M, SPORTIF Investigators.
    J Intern Med; 2008 Jul 23; 264(1):50-61. PubMed ID: 18266660
    [Abstract] [Full Text] [Related]

  • 54. Prestroke anticoagulation and paroxysmal type are correlated with favorable outcome in ischemic stroke patients with atrial fibrillation.
    Hoshino H, Itoh Y, Kimura H, Miyaki K, Suzuki N.
    J Stroke Cerebrovasc Dis; 2012 Jan 23; 21(1):11-7. PubMed ID: 20833081
    [Abstract] [Full Text] [Related]

  • 55. Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial.
    Pérez-Gómez F, Iriarte JA, Zumalde J, Berjón J, Salvador A, Alegría E, Maluenda MP, Asenjo S, Perez-Saldaña R, de la Torre RG, Bover R, Fernández C.
    Eur Heart J; 2007 Apr 23; 28(8):996-1003. PubMed ID: 17158523
    [Abstract] [Full Text] [Related]

  • 56. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
    Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M, CCS Atrial Fibrillation Guidelines Committee.
    Can J Cardiol; 2011 Apr 23; 27(1):74-90. PubMed ID: 21329865
    [Abstract] [Full Text] [Related]

  • 57. Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project.
    Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, Vicente V, Valdés M, Marín F, Lip GYH.
    Thromb Haemost; 2017 Oct 05; 117(10):1848-1858. PubMed ID: 28799620
    [Abstract] [Full Text] [Related]

  • 58. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients.
    Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, Maywald U, Kohlmann T, Feng YS, Breithardt G, Bauersachs R.
    Thromb Haemost; 2012 Jun 05; 107(6):1053-65. PubMed ID: 22398417
    [Abstract] [Full Text] [Related]

  • 59. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
    Eikelboom JW, O'Donnell M, Yusuf S, Diaz R, Flaker G, Hart R, Hohnloser S, Joyner C, Lawrence J, Pais P, Pogue J, Synhorst D, Connolly SJ.
    Am Heart J; 2010 Mar 05; 159(3):348-353.e1. PubMed ID: 20211294
    [Abstract] [Full Text] [Related]

  • 60. Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice.
    Abdelhafiz AH, Wheeldon NM.
    Am J Geriatr Pharmacother; 2008 Mar 05; 6(1):1-11. PubMed ID: 18396243
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.